Abstract：ObjectiveTo explore the clinical efficacy of Argatroban combined with Edaravone in the treatment of atrial fibrillation complicated with cerebral embolism.Methods76 patients with atrial fibrillation and cerebral embolism admitted into our hospital from March 2014 to May 2016 were selected.Based on dynamic random classification,they were divided into research group (n=38)and control group (n=38).The patients in the control group were treated with Low Molecular Weight Heparin and the patients in the research group were treated with Argatroban combined with Edaravone.The score of national institutes of health stroke scale （NIHSS),Barthel score of activities of daily living,and coagulation indicator between two groups were compared.ResultsThere was no statistical difference in NIHSS score or Barthel score between two groups before treatment(P＞0.05).After therapy,the score of NIHSS was(9.15±2.12)points, and Barthel score was（76.57±14.23)points,which caught great superiority in comparison with those in the control group [(15.47±4.35)points,(58.45±12.31)points](P＜0.05).No great difference was displayed in the coagulation indicator before treatment(P＞0.05),but after therapy,the advantage was greater in the research group compared with that in the control group (P＜0.05).ConclusionArgatroban combined with Edaravone in the treatment of atrial fibrillation complicated with cerebral embolism can effectively improve neurologic impairment,ability of daily life activities,as well as coagulation indicator,which is worthy of widespread promotion in clinic.
Kim SJ，Shin HY，Ha YS，et al.Paradoxical embolism as a cause of silent brain infarctions in healthy subjects：the ICONS study（Identification of the Cause of Silent Cerebral Infarction in Healthy Subjects）[J].Eur J Neurol，2013，20（2）：353-360.
京公网安备 11010502046607号